Statistics from Altmetric.com
Drug-eluting stents (DES) drastically improved the efficacy of percutaneous coronary intervention by reducing the risk of in-stent restenosis (ISR) and subsequent need of target lesion revascularisation (TLR). However, despite the advances in DES technology, the incidence of ISR is still significant and considering that more than five million DES are implanted each year worldwide, ISR can be considered an issue of public health magnitude. Percutaneous treatment strategies for ISR have been investigated since its first appearance in the bare-metal stent (BMS) era, however uncertainty still exists regarding the optimal therapeutic approach to implement in clinical practice. In a recent study, Giacoppo and colleagues tried to shed light on this uncertainty through a network meta-analysis of randomised controlled trials (RCTs) investigating …
Competing interests RM has received consultant and speaker honoraria (modest level) from Bristol-Myers Squibb, Sanofi-Aventis, Eli Lilly, Daiichi Sankyo, Abbott Vascular, AstraZeneca, Boston Scientific, and Johnson & Johnson.
Provenance and peer review Commissioned; internally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.